多发性硬化患者血清与脑脊液中白介素6及其可溶性受体成分sIL-6Rs、gp130的研究

Study on the CSF and Serum Levels of Interleukin-6 and Its Soluble Receptors(sIL-6R,sgp130) in the Multiple Sclerosis

目的为探讨IL-6及其可溶性受体在多发性硬化(MS)体液免疫异常中的作用。方法采用ELISA法测定了MS患者血清和脑脊液中IL-6及其可溶性受体成分(sIL-6R、sgp130)的水平,并与非MS的神经系统疾病、非MS神经系统炎症性疾病以及对照组进行组间比较。结果MS患者血清及脑脊液中IL-6水平与对照组相比差异无显著性,仅见脑脊液sIL-6R升高,且其血清水平与脑脊液水平呈正相关;同时血清sgp130水平升高而脑脊液sgp130水平减低。与MS组不同,在神经系统炎症性疾病组三者血清和脑脊液水平均有升高。结论研究结果提示sIL-6R、sgp130可能通过调控IL-6活性参与MS发病,与一般神经系统炎症性疾病相比MS的发病可能有某些不同的体液免疫机制。

Objective To observe the varied CSF and serum level of IL-6 and its soluble receptors （sIL-6R, sgp130） in multiple sclerosis（MS）. Methods By using the ELESA technique, the concentrations of cytokine IL- 6 and sIL-6R,sgp130 were measured both in serum and CSF, and were compared among MS, non-MS neurological diseases（nMSND）, non-MS inflammatory neurological diseases（nMSIND） and controls. Results In MS, the IL-6 concentrations were unchanged both in CSF and serum, whereas CSF sIL-6 were higher, and CSF sgp130 were lower significantly when compared to nMSND and controls. However, the three components were highest in nMSIND when compared to the other groups. Conclusions The data indicates that sIL-6R, sgp130 might contribute to the MS pathogenic mechanism by regulating the biological effects of IL-6, and has its variant humoral immunodisorders from the nop-MS inflammatory neurological diseases.